KZA Media Thread, page-1274

https://unauthorised investment advice/health/clinical-trial-tracker-the-tests-asx-healthcare-companies-have-upcoming-in-2021/

Given its size, Kazia Therapeutics (ASX:KZA), a $160 million Sydney company developing treatments for brain and ovarian cancer, was a standout in our tracker with the amount of research underway.

Kazia chief executive and executive director Dr James Garner told * that the Sydney company had eight different clincial trials in progress – seven in collaboration with world-renown organisations including the Dana-Farber Cancer Institute in Boston and the Memorial Sloan Kettering Cancer Center in New York City.

“We wanted to put into place a very international-grade research program,” to add value to Kazia’s assets while avoiding the trap some Australian biopharmaceutical companies run into of running from financing round to financing round, Dr Garner said.

Partnerships give Kazia the best “bang for the buck” even if the company loses some control over the process, he said.

Only one of Kazia’s clinical trials is explicitly designed as a “pivotal” study, meaning one that could be used to apply for a regulatory approval. But given that some of the research is into very rare pediatric brain cancers, regulators might accept the results of one of the smaller studies to progress a drug to market, Dr Garner said.